John Bujnoski

About John Bujnoski

Strategic, patient and customer-centric biopharmaceutical executive with 25+ years of experience leading U.S. and global commercialization, portfolio value creation, and business development across dermatology and inflammatory diseases. Proven track record of P&L management ($600M+), accelerating growth, and strengthening brand equity for specialty therapies in highly competitive markets.Currently Vice President and Head of the Dermatology & Immunology Business Unit at Sun Pharma, with responsibility for a portfolio including Ilumya® (psoriasis), Leqselvi® (alopecia areata), and Winlevi® (acne). I collaborate with cross functional teams to develop commercial strategy and drive enterprise alignment across Medical Affairs, Market Access, Clinical Development, and Regulatory, ensuring compliant, patient-focused engagement that improves access, outcomes, and long-term value.Recognized for building and leading high-performing commercial organizations (200+ employees), modernizing go-to-market models through data, analytics, AI, and omnichannel execution, and integrating real-world insights into brand strategy and evidence generation. I focus on deeply understanding the unmet needs of patients, prescribers, and payers, and translating those insights into differentiated value propositions and sustainable growth.Extensive global experience, including living and working in Europe for more than five years, leading pan-European and global teams, executing complex launches, and navigating diverse reimbursement environments.Throughout my career, I have played an active role in business development, portfolio and lifecycle management, ensuring deep commercial insights are reflected in R&D and clinical development decisions.Core CapabilitiesEnterprise & Strategic LeadershipP & L ownership • Portfolio strategy • Organizational alignment • Executive and Board engagementDermatology & Immunology ExpertisePsoriasis • Alopecia areata • Atopic dermatitis • Psoriatic arthritis • Rheumatoid arthritisCommercial & Launch ExcellenceGlobal and U.S. launches • Lifecycle strategy • OmnichannelEarlier Career HighlightsPfizer: Progressive growth and advanced through marketing roles of increasing responsibility across U.S. and European. 8 years’ experience working on Enbrel® across multiple indications, developing deep expertise in immunology, payer strategy, and global commercialization.Merck: Held a series of sales and marketing roles with increasing responsibility building a strong foundation in customer-centricity, data-driven strategy, and execution excellence.

Experience

1. Vice President, Head of Us Dermatology & Immunology Business Unit

   SUN PHARMA

   Oct 2024 — Present · US

   Provide strategic and operational leadership for Sun Pharma’s Dermatology & Immunology Business Unit, defining the long-term commercialization vision and driving enterprise alignment across Medical Affairs, Market Access, Clinical Development, and Regulatory Affairs. Accountable for accelerating portfolio growth, strengthening brand equity, and ensuring compliant, patient-centric engagement across dermatology and immunology.Full P&L responsibility for a $600M+ portfolio and leading a 200+ person Sales and Marketing organization. Portfolio includes Ilumya® (psoriasis), Leqselvi® (alopecia areata), and Winlevi® (acne).Key Achievements & ResponsibilitiesDeveloped and executed portfolio strategy across dermatology and immunology, delivering double-digit revenue growth and EBITA growth.Strengthened competitiveness through advanced analytics and real-time market intelligence, sharpening differentiation, messaging, and customer engagement.Led digital and data transformation, embedding AI-driven insights, predictive analytics, and machine learning to modernize field operations, expand omnichannel reach, and improve promotional ROI.Lead a high-performance, patient- and customer-centric organization, strengthening collaboration with healthcare professionals, payers, and patient advocacy groups.Directed lifecycle management and business development initiatives, including portfolio expansion, in-licensing assessments, and strategic partnerships aligned with long-term enterprise growth.Influenced enterprise and global strategy by integrating commercial perspectives into R&D, access, and regulatory decisions to maximize asset value across the pipeline.

Skills

• Strategic Leadership
• Marketing Strategy
• Pricing Strategy
• Product Life Cycle Management
• Pharmaceutical Sales
• Sales Management
• Pricing Policy
• Global Marketing
• Global Strategy
• Cross-Functional Team Leadership
• Team Leadership
• Profit & Loss Management
• Product Launch
• P&L Management
• Commercialization
• Strategy
• Strategic Planning
• Leadership
• Management
• Product Lifecycle Management
• Business Strategy
• Biotechnology
• Rheumatology
• Market Planning
• Pharmaceutical Industry
• Infectious Diseases
• Market Access
• Vaccines
• Biopharmaceuticals
• Pharmaceutics
• Marketing
• Hospital Sales
• Dermatology
• Managed Care
• Lifesciences
• Immunology
• Life Sciences
• International Marketing